Veristat, a global clinical research organization (CRO) and consultancy specializing in complex clinical studies, announced its participation in the upcoming Clinical Outsourcing Group (COG) – Bay Area 2025 conference, to be held October 21–22, 2025, at the Hyatt Regency San…
AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing proprietary nebulized combination therapies for chronic respiratory diseases, announced the successful closing of a $21 million Series A financing. The funding round was led by Avalon BioVentures, with additional participation…
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical-stage cell therapy company, have announced encouraging 36-month follow-up data from exPDite, a Phase I clinical trial investigating bemdaneprocel, an investigational stem cell-derived therapy designed to treat…
The global oncology landscape continues to evolve at a rapid pace, driven by a growing understanding of tumor immunology and the mechanisms that cancer cells exploit to evade immune destruction. Among the most promising targets in this field is CD47,…
Rahway, N.J. – Merck, known as MSD outside the United States and Canada, announced the initiation of three new Phase 2b clinical trials to evaluate the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody designed to target…
The University of Phoenix College of Doctoral Studies has unveiled a new white paper titled “Reinventing Productivity: Aligning AI Innovation with Human Potential in the Modern Workforce.” Authored by Jessica Sylvester, Ed.D., MBA, Senior Manager of College Operations, associate faculty…
Neuraptive Therapeutics, Inc., a biotechnology company developing novel therapies to improve outcomes for patients with peripheral nerve injuries (PNI), announced the enrollment of the first patient in its pivotal Phase 3 clinical trial evaluating NTX-001, a novel therapeutic designed to…
iECURE, Inc., a clinical-stage genome editing company pioneering variant-agnostic in vivo targeted gene insertion therapies for severe liver disorders, announced that new data from the ongoing OTC-HOPE clinical trial evaluating its lead candidate ECUR-506 will be presented at two of…
AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company focused on developing novel therapies for serious cardiopulmonary diseases, today announced compelling new preclinical results for its investigational therapy ALG-801. The data show that ALG-801 delivered superior efficacy compared with current standard-of-care…
CytoAgents, Inc., a clinical-stage biotechnology company focused on developing safe and effective preventative therapies for life-threatening immune-related toxicities, today announced it has been awarded a $2.25 million grant from the National Institutes of Health (NIH). This grant, issued through the…